X

Trial Profile

Safety and efficacy of IMM-101 combined with stereotactic radiotherapy in patients with limited MEtastatic PANcreatic Cancer (MEPANC-1)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IMM 101 (Primary)
Indications Cancer metastases; Liver metastases; Pancreatic cancer
Focus Adverse reactions; Therapeutic Use
Acronyms MEPANC-1

Most Recent Events

25 Mar 2021 According to an Immodulon Therapeutics media release, this study is conducted in collaboration with Professor van Eijck and his team at the Erasmus University Medical Center Rotterdam.
25 Mar 2021 According to an Immodulon Therapeutics media release, first patient has been enrolled in this trial.
18 Jan 2021 Status changed from planning to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com